Cantor Fitzgerald Maintains Overweight on Viking Therapeutics, Lowers Price Target to $100

Benzinga Newsdesk www.benzinga.com Negative 82.3%

Neg 82.3% Neu 0% Pos 0%

Cantor Fitzgerald analyst Steve Seedhouse maintains Viking Therapeutics (NASDAQ:VKTX) with a Overweight and lowers the price target from $105 to $100.